- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07492524
Telemedicinbaserad integrerad behandling av förmaksflimmer och hjärtsvikt hos äldre patienter i bykliniker
Telemedicinbaserad Integrerad Hantering av Förmaksflimmer och Hjärtsvikt hos Äldre Patienter i Bykliniker: MIRACLE-AF II Klusterrandomiserad Studie
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Förmaksflimmer (AF) och hjärtsvikt (HF) förekommer ofta tillsammans och förstärker varandra, vilket bildar en "ond cirkel" som är särskilt förödande för äldre vuxna. Äldre patienter med AF löper hög risk för HF-progression, och AF-HF-samjuklighet är en central faktor för långsiktig prognos. I landsbygdsområden i Kina står effektiv prevention och långsiktig hantering inför praktiska flaskhalsar, inklusive otillräcklig tidig HF-screening och otillräcklig intensitet av målriktad prevention. Tidigare studier tyder på att endast "processorienterad" integration, såsom den standardiserade ABC-vägen, kan vara otillräcklig för landsbygds-AF-patienter där HF-risk är dominerande.
För att adressera dessa luckor syftar MIRACLE-AF II-studien till att etablera en modell ledd av byläkare som integrerar riktlinjestyrd medicinsk behandling (GDMT) med flerdimensionella livsstilsinterventioner, med stöd av telemedicin och intelligent beslutsstöd. Genom att integrera tidig HF-screening, läkemedelsåtkomst och en skalbar livsstilsintervention (inklusive peer-grupp hjärtrehabilitering, beteendeutbildning och smarta wearables övervakning) i ett tele-stött arbetsflöde, strävar detta projekt efter att effektivt förbättra kliniska utfall för äldre patienter.
Detta är ett klusterrandomiserat kontrollerat försök som genomförs i landsbygdsområden i Jiangsu-provinsen, Kina. Byläkarmottagningar randomiseras i ett 1:1-förhållande till antingen en digital intelligent integrerad hanteringsgrupp (intervention) eller en konventionell hanteringsgrupp (kontroll). Studien rekryterar permanent bosatta invånare i åldern 65 till 80 år med bekräftad AF och en dokumenterad historia eller screeningbaserad diagnos av HF. Försöket är uppdelat i två faser: en 12-månadersuppföljning för att jämföra HF-prognospoängen (MAGGIC-poäng) mellan de två grupperna, och en 36-månadersuppföljning för att jämföra sammansatta slutpunktshändelser, inklusive kardiovaskulär död, ischemisk eller hemorragisk stroke, sjukhusinläggning på grund av försämrad HF eller akut koronart syndrom (ACS), och akutbesök för AF.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Ming Chu
- Telefonnummer: 13814010410
- E-post: chuming@njmu.edu.cn
Studieorter
-
-
Dongtai
-
Yancheng, Dongtai, Kina, 224200
- Rekrytering
- Village Clinics in Dongtai City, Jiangsu Province
-
Kontakt:
- Cheng Wu
- Telefonnummer: 18012515515
- E-post: wucheng1413@163.com
-
-
Jiangdu
-
Yangzhou, Jiangdu, Kina, 225267
- Rekrytering
- Village Clinics in Jiangdu District, Jiangsu Province
-
Kontakt:
- Ming Chu
- Telefonnummer: 13814010410
- E-post: chuming@njmu.edu.cn
-
-
Suining
-
Xuzhou, Suining, Kina, 221200
- Rekrytering
- Village Clinics in Suining County, Jiangsu Province
-
Kontakt:
- Wensu Chen
- Telefonnummer: 15050848274
- E-post: Chen.wensu@163.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inklusionskriterier:
- Fastboende med lokal hushållsregistrering på primärnivå i Jiangsu-provinsen, 65–80 år gamla.
- Elektrokardiogram (EKG) bekräftelse av förmaksflimmer eller innehav av ett diagnostiskt intyg för förmaksflimmer utfärdat av en specialist.
- En dokumenterad historia av hjärtsvikt eller en diagnos av hjärtsvikt baserad på ekkardiografi och/eller NT-proBNP-screening, definierad av närvaron av typiska hjärtsviktsymtom och/eller tecken, tillsammans med en av följande: reducerad vänsterkammarutstötningsfraktion (HFrEF; LVEF < 40%), lätt reducerad vänsterkammarutstötningsfraktion (HFmrEF; LVEF 40–49%) eller bevarad vänsterkammarutstötningsfraktion med förhöjd NT-proBNP och strukturella hjärtförändringar (HFpEF; LVEF ≥ 50%, uppfyller minst ett av följande kriterier: LAV 40 ml/m², E/e' ≥ 15, eller TRV > 2,8 m/s).
- Hantering av en byklinik nära deltagarens bostadsort.
- Förmåga att förstå studieprocedurerna och ge skriftligt informerat samtycke.
Exklusionskriterier:
- Förväntad livslängd mindre än 3 månader.
- Svår njurinsufficiens (Ccr < 30 ml/min) eller pågående dialysbehandling.
- Hjärtsvikt sekundärt till korrigerbara orsaker, inklusive tyreotoxisk hjärtsjukdom, anemisk hjärtsjukdom eller okorrigerad medfödd hjärtsjukdom.
- Indikationer för pacemakerimplantation utan att ha genomgått implantation.
- Kroniskt obstruktiv lungsjukdom (KOL) komplicerad av typ II respiratorisk svikt.
- Specialpopulationer, inklusive patienter med psykiska sjukdomar.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Intervention Group
Participants in this arm will receive village-doctor led integrated care for atrial fibrillation and heart failure.
Village doctors will receive standardized training based on the AF ABC pathway and heart failure GDMT principles.
Patients will receive structured self-management education focused on medication adherence, symptom monitoring, lifestyle modification, and recognition of warning signs.
|
|
|
Aktiv komparator: Control Group
Participants in this arm will receive usual chronic disease management according to the National Basic Public Health Service requirements.
|
Usual care includes routine follow-up, general health education, medication registration, and standard referral procedures provided by local primary care providers.
Participants will not receive the structured village-doctor led integrated care program.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in MAGGIC Heart Failure Risk Score
Tidsram: Baseline to 12 months
|
A heart failure prognostic model integrating 13 key predictors, including age, LVEF, systolic blood pressure, BMI, serum creatinine, NYHA functional class, and medication status.
|
Baseline to 12 months
|
|
Composite Cardiovascular Endpoint
Tidsram: 36 months after baseline
|
Composite cardiovascular endpoint, including cardiovascular death, ischemic or hemorrhagic stroke, hospitalization for worsening heart failure or acute coronary syndrome, and emergency visits due to atrial fibrillation.
|
36 months after baseline
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Cardiovascular Death
Tidsram: 12 months after baseline
|
Cardiovascular death was defined as death attributable to myocardial infarction, heart failure, arrhythmia, cardiac perforation or tamponade, or other deaths of cardiac origin.
Death caused by ischemic stroke, hemorrhagic stroke, peripheral embolism, and pulmonary embolism was also classified as cardiovascular death
|
12 months after baseline
|
|
Cardiovascular Hospitalization
Tidsram: 12 months after baseline
|
Hospitalization due to cardiovascular or neurological diseases at township-level or higher hospitals, including heart failure, cardiac arrhythmia, acute coronary syndrome, hypertensive emergency or urgency, ischemic or hemorrhagic stroke, and transient ischemic attack.
|
12 months after baseline
|
|
Emergency Visit for Cardiovascular Events
Tidsram: 12 months after baseline
|
Incidence of emergency visits for cardiovascular events, including exacerbation of heart failure or acute coronary syndrome.
|
12 months after baseline
|
|
ischemic or hemorrhagic Stroke
Tidsram: 12 months after baseline
|
All strokes: ischemic or hemorrhagic Stroke
|
12 months after baseline
|
|
The proportion of patients who met all the three criteria for the ABC pathway of integrated AF care
Tidsram: 12 month after baseline
|
The 'A' criterion referred to stroke prevention or anticoagulation.
'A criterion compliant' implies that either appropriate non-vitamin K antagonist oral anticoagulant (NOACs) use, or warfarin was used with a time in the therapeutic range (TTR) >65%.
Patients who were not properly treated with OACs are considered as 'A non-compliant'.
The 'B' criterion referred to better symptom control with patient-centered decisions on rate or rhythm control.
Patients with an EHRA score of I or II are considered to have good control of AF symptoms ('B compliant').
On the contrary, those with an EHRA score of III or IV were defined as 'B non-compliant', which means their symptoms were insufficiently controlled.
The 'C' criterion stands for optimal management of cardiovascular risk factors and other comorbidities.
'C criterion compliant' implies that all the considered risk factors and comorbidities were well controlled or optimally treated.
Otherwise, patients were considered as 'C non-compliant'
|
12 month after baseline
|
|
GDMT medication utilization rate
Tidsram: 12months after baseline
|
The proportion of patients who are eligible for guideline-directed medical therapy (GDMT) and actually receive GDMT within 12 Months.
Single-class prescription rate: Prescription rate for a given GDMT drug class = (number of patients prescribed that drug class) / (number of patients eligible for that drug class) × 100%.
At least one GDMT class prescription rate: At least one GDMT prescription rate = (number of patients prescribed at least one GDMT drug class) / (total number of patients eligible for GDMT) × 100%.
Quadruple GDMT prescription rate: Quadruple therapy prescription rate = (number of patients simultaneously prescribed ARNI/ACEI/ARB + β-blocker + MRA + SGLT2 inhibitor) / (number of patients eligible for all four drug classes) × 100%.
|
12months after baseline
|
|
Cardiovascular Death
Tidsram: 36 months after baseline
|
Cardiovascular death was defined as death attributable to myocardial infarction, heart failure, arrhythmia, cardiac perforation or tamponade, or other deaths of cardiac origin.
Death caused by ischemic stroke, hemorrhagic stroke, peripheral embolism, and pulmonary embolism was also classified as cardiovascular deathTime
|
36 months after baseline
|
|
Ischemic or hemorrhagic Stroke
Tidsram: 36 months after baseline
|
All strokes: ischemic or hemorrhagic Stroke
|
36 months after baseline
|
|
Worsening of heart failure or acute coronary syndrome
Tidsram: 36 months after baseline
|
A worsening of heart failure or acute coronary syndrome was defined as the need to be hospitalized or have an emergency visit in conjunction with these conditions
|
36 months after baseline
|
|
Emergency visit due to AF
Tidsram: 36 months after baseline
|
Emergency visit due to AF
|
36 months after baseline
|
|
All-cause mortality
Tidsram: 36 months after baseline
|
all-cause death
|
36 months after baseline
|
|
The proportion of patients who met all the three criteria for the ABC pathway
Tidsram: 36 month after baseline
|
The 'A' criterion referred to stroke prevention or anticoagulation.
'A criterion compliant' implies that either appropriate non-vitamin K antagonist oral anticoagulant (NOACs) use, or warfarin was used with a time in the therapeutic range (TTR) >65%.
Patients who were not properly treated with OACs are considered as 'A non-compliant'.
The 'B' criterion referred to better symptom control with patient-centered decisions on rate or rhythm control.
Patients with an EHRA score of I or II are considered to have good control of AF symptoms ('B compliant').
On the contrary, those with an EHRA score of III or IV were defined as 'B non-compliant', which means their symptoms were insufficiently controlled.
The 'C' criterion stands for optimal management of cardiovascular risk factors and other comorbidities.
'C criterion compliant' implies that all the considered risk factors and comorbidities were well controlled or optimally treated.
Otherwise, patients were considered as 'C non-compliant'
|
36 month after baseline
|
|
Change in MAGGIC Heart Failure Risk Score
Tidsram: Baseline to 36 months
|
Description: A heart failure prognostic model integrating 13 key predictors, including age, LVEF, systolic blood pressure, BMI, serum creatinine, NYHA functional class, and medication status.
|
Baseline to 36 months
|
|
GDMT Score
Tidsram: Baseline to 12 months
|
β-blockers are scored as 0, 1, or 2 points for no use, use at <50% of the target dose, or use at ≥50% of the target dose, respectively.
For renin-angiotensin system inhibitors, no use is scored as 0 points; ACEI/ARB therapy at <50% or ≥50% of the target dose is scored as 1 or 2 points, respectively; and ARNI therapy at any dose is scored as 3 points.
Mineralocorticoid receptor antagonists and SGLT2 inhibitors are each scored as 0 points when not used and 2 points when used at any dose.
Ivabradine and vericiguat are each scored as 0 points when not used and 1 point when used at any dose.
The scores for all medication classes are summed to obtain the total GDMT score, with a higher score indicating a greater degree of GDMT implementation.
Target doses are determined according to the relevant heart failure guidelines.
|
Baseline to 12 months
|
|
GDMT Score
Tidsram: Baseline to 36 months
|
β-blockers are scored as 0, 1, or 2 points for no use, use at <50% of the target dose, or use at ≥50% of the target dose, respectively.
For renin-angiotensin system inhibitors, no use is scored as 0 points; ACEI/ARB therapy at <50% or ≥50% of the target dose is scored as 1 or 2 points, respectively; and ARNI therapy at any dose is scored as 3 points.
Mineralocorticoid receptor antagonists and SGLT2 inhibitors are each scored as 0 points when not used and 2 points when used at any dose.
Ivabradine and vericiguat are each scored as 0 points when not used and 1 point when used at any dose.
The scores for all medication classes are summed to obtain the total GDMT score, with a higher score indicating a greater degree of GDMT implementation.
Target doses are determined according to the relevant heart failure guidelines.
|
Baseline to 36 months
|
|
GDMT medication utilization rate
Tidsram: 36 months after baseline
|
The proportion of patients who are eligible for guideline-directed medical therapy (GDMT) and actually receive GDMT within 36 months.
Single-class prescription rate: Prescription rate for a given GDMT drug class = (number of patients prescribed that drug class) / (number of patients eligible for that drug class) × 100%.
At least one GDMT class prescription rate: At least one GDMT prescription rate = (number of patients prescribed at least one GDMT drug class) / (total number of patients eligible for GDMT) × 100%.
Quadruple GDMT prescription rate: Quadruple therapy prescription rate = (number of patients simultaneously prescribed ARNI/ACEI/ARB + β-blocker + MRA + SGLT2 inhibitor) / (number of patients eligible for all four drug classes) × 100%.
|
36 months after baseline
|
Samarbetspartners och utredare
Samarbetspartners
Publikationer och användbara länkar
Allmänna publikationer
- Chu M, Zhang S, Gong J, Yang S, Yang G, Sun X, Wu D, Xia Y, Jiao J, Peng X, Peng Z, Hong L, Wang Z, Li M, Lip GYH, Chen M; MIRACLE-AF Investigators. Telemedicine-based integrated management of atrial fibrillation in village clinics: a cluster randomized trial. Nat Med. 2025 Apr;31(4):1276-1285. doi: 10.1038/s41591-025-03511-2. Epub 2025 Feb 21.
- Li M, Chu M, Shen Y, Zhang S, Yin X, Yang S, Lip GYH, Chen M; MIRACLE-AF Trial Investigators. A Novel Model of Integrated Care of Older Patients With Atrial Fibrillation in Rural China. JACC Asia. 2024 Jul 30;4(10):764-773. doi: 10.1016/j.jacasi.2024.07.006. eCollection 2024 Oct.
- Li M, Chen Y, Chu M, Zhang S, Yang S, Lip GYH, Chen M. Village Doctor-Led Telemedicine for Rural Patients Aged 75 Years and Older With AF: A Prespecified Secondary Analysis of the MIRACLE-AF Trial. JAMA Netw Open. 2026 Mar 2;9(3):e261385. doi: 10.1001/jamanetworkopen.2026.1385.
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- LSKY 2025-192-01,2026-SR-177
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .